These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21525886)

  • 1. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis.
    Sandoo A; Panoulas VF; Toms TE; Smith JP; Stavropoulos-Kalinoglou A; Metsios GS; Gasparyan AY; Carroll D; Veldhuijzen van Zanten JJ; Kitas GD
    J Hum Hypertens; 2011 Nov; 25(11):699-702. PubMed ID: 21525886
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
    J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163
    [No Abstract]   [Full Text] [Related]  

  • 6. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.
    Pincus T; Yazici Y; van Vollenhoven R
    J Rheumatol; 2006 Dec; 33(12):2372-5. PubMed ID: 17143975
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 8. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 9. Rheumatoid arthritis.
    Burchini G; Orsi C
    N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).
    Iannone F; Ferraccioli G; Gremese E; Lapadula G;
    Ann Rheum Dis; 2014 Jun; 73(6):e31. PubMed ID: 24368512
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
    Ledingham J; Deighton C;
    Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs for rheumatoid arthritis.
    Messori A; Santarlasci B; Vaiani M
    N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 16. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 17. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

  • 18. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review.
    Dulai R; Perry M; Twycross-Lewis R; Morrissey D; Atzeni F; Greenwald S
    Semin Arthritis Rheum; 2012 Aug; 42(1):1-8. PubMed ID: 22475245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.